Abstract | PURPOSE: EXPERIMENTAL DESIGN: To investigate the potential of STI571 as therapy for osteosarcoma, we studied its effects on PDGF-mediated cell growth in vitro and in an in vivo mouse model. RESULTS: CONCLUSIONS: Our data demonstrate that STI571 inhibits PDGF-mediated growth and leads to apoptosis of osteosarcoma cells in vitro by selective inhibition of the PDGFR tyrosine kinase. The effectiveness of STI571 in our studies suggests targeting of PDGFRs as a novel treatment for osteosarcoma.
|
Authors | Eric C McGary, Kristy Weber, Lisa Mills, Michelle Doucet, Valerie Lewis, Dina Chelouche Lev, Isaiah J Fidler, Menashe Bar-Eli |
Journal | Clinical cancer research : an official journal of the American Association for Cancer Research
(Clin Cancer Res)
Vol. 8
Issue 11
Pg. 3584-91
(Nov 2002)
ISSN: 1078-0432 [Print] United States |
PMID | 12429650
(Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Antineoplastic Agents
- Benzamides
- Enzyme Inhibitors
- Piperazines
- Platelet-Derived Growth Factor
- Pyrimidines
- Imatinib Mesylate
- Protein-Tyrosine Kinases
- Proto-Oncogene Proteins c-kit
- Receptors, Platelet-Derived Growth Factor
- Paclitaxel
|
Topics |
- Animals
- Antineoplastic Agents
(pharmacology)
- Benzamides
- Blotting, Western
- Bone Neoplasms
(metabolism, pathology)
- Cell Division
- Cell Line, Transformed
- Enzyme Inhibitors
(pharmacology)
- Female
- Humans
- Imatinib Mesylate
- In Situ Nick-End Labeling
- Mice
- Neoplasm Transplantation
- Osteosarcoma
(drug therapy, metabolism)
- Paclitaxel
(pharmacology)
- Phosphorylation
- Piperazines
(pharmacology)
- Platelet-Derived Growth Factor
(antagonists & inhibitors)
- Protein-Tyrosine Kinases
(antagonists & inhibitors)
- Proto-Oncogene Proteins c-kit
(metabolism)
- Pyrimidines
(pharmacology)
- Receptors, Platelet-Derived Growth Factor
(metabolism)
- Signal Transduction
- Tibia
(metabolism)
- Time Factors
- Tumor Cells, Cultured
|